# Pyrotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pyrotech

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.pyrotech.com
- Total disclosed funding: $97M
- Latest round: Series A (May 24, 2024)
- Investors on record: 14

## About

Based in Beijing, China, and founded in 2020, Pyrotech (Beijing) Biotechnology Co., Ltd., trading as Pyrotech, is a pharmaceutical R&D and manufacturing company that primarily provides services such as drug production and wholesale, R&D of biopharmaceutical technologies and products, technical services, technology transfer, and technical consulting. It has R&D centers in Beijing and Shanghai and BD and clinical centers in the US. The co-founder and CEO of the company, Tianjing Deng, graduated from Marquette University and has founded BioDuro. In July 2026, Pyrotech raised a Pre-series B funding led by Shanghai State-owned Capital Investment Leading Fund, with particpation from Zhongguancun Science City Capital, Shanghai Minhang Financial Investment Development, Septwolves Holding, China Reform Holdings, Shunxi Fund, Green Waters Fund, Frees Fund, Changkejin Investment, Lccap, and other investors.

The company focuses on cellular scorching in the field of disease treatment, including inflammatory diseases and tumors. It develops three technology platforms, which are small molecule immunomodulatory new drug research and development platform, biological regulation pyroptosis technology platform, and disease translation research platform. Pyrotech's R&D product pipeline includes three modes of agonists, gene regulation, and inhibitors. The treatment directions of the product pipeline include tumor immunity, hereditary disease, sepsis, kidney damage, asthma, etc.

The company generates revenue by providing self-developed technology platforms to develop small molecule drugs in the fields of inflammation and oncology, as well as other disease areas.

The Pre-series B funding raised in July 2026 will be used to support the development and implementation of the cell pyroptosis bio-regulation drug R&D technology platform at its Shanghai subsidiary, as well as the clinical advancement of multiple projects at its Beijing small molecule immunomodulator drug R&D platform, accelerating the progress of several preclinical projects and further expanding its R&D pipeline.

## Funding rounds

- Series A, May 24, 2024 — Lilly Asia Ventures, China Reform Holdings, Shunxi Fund, Beijing Baheal Zhongxin Kangjian Investment Management, Green Waters Fund, Taiping Innovation Investment Management, Lccap, Frees Fund
- Series A, Jul 10, 2023, $97M — Lilly Asia Ventures, MSA Capital, Lotus Lake Capital, Frees Fund, China Reform Holdings, SDIC Venture Capital, Changkejin  Investment, BioTrack Capital, Green Waters Fund, Taiping Innovation Investment Management, Lccap, China Life Capital
- Angel, Jan 17, 2021 — Lilly Asia Ventures, MSA Capital, Frees Fund, Changkejin  Investment, BioTrack Capital, Green Waters Fund, Lccap

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Angel, Series A
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Angel, Series A
- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Angel, Series A
- Changkejin  Investment — Angel, Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Angel, Series A
- Green Waters Fund — Angel, Series A
- Lccap — Angel, Series A
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series A
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A
- Taiping Innovation Investment Management — Series A
- China Life Capital — Series A
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series A
- Beijing Baheal Zhongxin Kangjian Investment Management (https://capitalatlas.ai/funds/beijing-baheal-zhongxin-kangjian-investment-management) — Series A